Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Boehringer Ingelheim
AstraZeneca
Daiichi Sankyo
Express Scripts
Healthtrust
US Department of Justice
Fish and Richardson
Chubb
Argus Health

Generated: October 20, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 078232

« Back to Dashboard
NDA 078232 describes LOSARTAN POTASSIUM, which is a drug marketed by Sandoz, Alembic Pharms Ltd, Watson Labs, Macleods Pharms Ltd, Unichem Labs Ltd, Lupin Ltd, Hetero Labs Ltd V, Viva Hlthcare, Zydus Pharms Usa Inc, Upsher-smith Labs, Teva, West-ward Pharms Int, Torrent Pharms, Cadista Pharms, Vivimed Global, Aurobindo Pharma, Apotex Corp, Ipca Labs Ltd, Mylan, Prinston Inc, Apotex, and Teva Pharms, and is included in thirty-five NDAs. It is available from sixty-six suppliers. Additional details are available on the LOSARTAN POTASSIUM profile page.

The generic ingredient in LOSARTAN POTASSIUM is hydrochlorothiazide; losartan potassium. There are thirty-one drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; losartan potassium profile page.

Summary for NDA: 078232

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 078232

Suppliers and Packaging for NDA: 078232

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LOSARTAN POTASSIUM
losartan potassium
TABLET;ORAL 078232 ANDA Lupin Pharmaceuticals, Inc. 68180-210 68180-210-01 100 TABLET in 1 BOTTLE (68180-210-01)
LOSARTAN POTASSIUM
losartan potassium
TABLET;ORAL 078232 ANDA Lupin Pharmaceuticals, Inc. 68180-210 68180-210-03 1000 TABLET in 1 BOTTLE (68180-210-03)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength25MG
Approval Date:Oct 6, 2010TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength50MG
Approval Date:Oct 6, 2010TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength100MG
Approval Date:Oct 6, 2010TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Johnson and Johnson
Julphar
Queensland Health
Covington
McKinsey
Citi
Cerilliant
US Army
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot